Brief: Alkermes Announces Initiation Of Vibrance-2 Phase 2 Study Evaluating Alks 2680 For The Treatment Of Narcolepsy Type 2
22/08/2024 12:39
Aug 22 (Reuters) - Alkermes Plc ALKS.O :
* ALKERMES ANNOUNCES INITIATION OF VIBRANCE-2 PHASE 2 STUDY
EVALUATING ALKS 2680 FOR THE TREATMENT OF NARCOLEPSY TYPE 2
* ALKERMES PLC - VIBRANCE-1 STUDY FOR NARCOLEPSY TYPE 1
CURRENTLY
ENROLLING
Source text for Eikon: ID:nPn4wZGcfa
Further company coverage: ALKS.O
((Reuters.Briefs@thomsonreuters.com;))